• Promising interim data from ACCENT trial of narmafotinib in advanced pancreatic cancer
• Objective response rate of 33%, superior to 23% for chemotherapy alone
• Initiated second trial (AMPLICITY) of narmafotinib with FOLFIRINOX

Amplia Therapeutics Limited (ASX: ATX) has announced its Appendix 4D and Financial Report for the Half Year ended 30 September 2025. The key focus for the company during the reporting period was on progressing the clinical studies of its lead asset narmafotinib in advanced pancreatic cancer. The ACCENT clinical trial, investigating the combination of narmafotinib with the chemotherapies gemcitabine and Abraxane, has recruited a total of 55 patients in the Phase 2a stage at sites in Australia and Korea. Promising interim data from the ACCENT trial was disclosed, including one patient achieving a complete response and another showing a pathological complete response. Importantly, an interim assessment of the primary clinical endpoint - the objective response rate (ORR) - was reported as 33%, notably superior to 23% recorded for chemotherapy alone. In addition, an interim measure of Progression Free Survival of 7.6 months was reported, representing a two-month improvement over the data for chemotherapy alone. The company also made progress in initiating the second clinical trial of narmafotinib, the AMPLICITY trial, where the combination of narmafotinib with the chemotherapy FOLFIRINOX is being explored. The company also announced a successful A$27.6 million capital raise to fund clinical and other planned activities into 2027.